Data to be presented in poster presentation beginning Friday November 7; selected for oral presentation Saturday November 8 at 1:40 PM in Exhibit Hall C.

ANN ARBOR, Mich. – October 31, 2014 Lycera Corp., a biopharmaceutical company developing breakthrough oral immune modulators to treat autoimmune disease and cancer, today announced that data on the anti-tumor activity of novel synthetic RORγ agonist product candidates will be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC) being held November 6-9, 2014 at the Gaylord National Hotel & Convention Center, National Harbor, MD. The poster, entitled “Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach“, will be presented beginning Friday, November 7. This poster also was selected by SITC to be highlighted in an oral presentation on November 8.

Poster: “Novel synthetic RORγ agonist compounds as a potential anti-tumor therapeutic approach”
Location: Society for Immunotherapy of Cancer Annual Meeting
Prince George’s Exhibit Hall C
Gaylord National Hotel and Convention Center
201 Waterfront St.
National Harbor, MD 20745
Dates: Poster presentation Friday, November 7 at 12:30-2:00 PM and 6:15-7:15 PM
Oral presentation at poster begins Saturday, November 8, at 1:40 PM
Presenter: Laura Carter, Ph.D., vice president, biology, Lycera Corp.

 

About Lycera
Lycera is a privately held biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression.

Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists, biologists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation. In addition to a robust proprietary pipeline, the company has an established research collaboration with Merck to discover, develop and commercialize small-molecule therapies for autoimmune disorders.